Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

350
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
350
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.4K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

383
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
383
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

375
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
375
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

886
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
886
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

371
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
371

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-Wide Association Study for Glucocorticoid-Induced Ocular Hypertension.

Ophthalmology science·2026
Same author

Diabetic Retinopathy: Genetics Deals the Cards, But Lifestyle Plays the Hand.

Ophthalmology·2026
Same author

Effect of Optical Coherence Tomography Angiography Image Artifacts on Quantitation of Vessel Density and Perfusion.

Ophthalmic surgery, lasers & imaging retina·2026
Same author

GWAS Meta-analysis Identifies Novel Associated Loci and Points to Causal Tissues in Central Serous Chorioretinopathy.

medRxiv : the preprint server for health sciences·2026
Same author

Prevalence and Risk Factors of Cystoid Macular Edema in Patients With Retinitis Pigmentosa in the United States: IRIS Registry Analysis.

Journal of vitreoretinal diseases·2026
Same author

CANCER-ASSOCIATED RETINOPATHY AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY.

Retinal cases & brief reports·2026
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Related Experiment Video

Updated: Dec 22, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.8K

Uveitis Therapy: The Corticosteroid Options.

Lianna M Valdes1, Lucia Sobrin2

  • 1Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA, 02114, USA.

Drugs
|May 1, 2020
PubMed
Summary
This summary is machine-generated.

Corticosteroids effectively treat uveitis by reducing intraocular inflammation. However, potential serious side effects limit their long-term use for this condition.

More Related Videos

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

738
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.0K

Related Experiment Videos

Last Updated: Dec 22, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

5.8K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

738
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

3.0K

Area of Science:

  • Ophthalmology
  • Immunology
  • Pharmacology

Background:

  • Uveitis involves intraocular inflammation with autoimmune/inflammatory or infectious causes.
  • Corticosteroids are crucial for managing uveitis, administered systemically or locally.
  • Available corticosteroid formulations include topical drops, periocular injections, intravitreal suspensions, and implants.

Purpose of the Study:

  • To review current corticosteroid treatment options for uveitis.
  • To detail the pros and cons of each corticosteroid therapy.
  • To discuss relevant clinical trials for corticosteroid treatments in uveitis.

Main Methods:

  • Literature review of available corticosteroid treatments for uveitis.
  • Analysis of favorable and unfavorable characteristics of each option.
  • Examination of applicable clinical trials.

Main Results:

  • Corticosteroids rapidly control uveitis inflammation.
  • Potential side effects include cataracts and elevated intraocular pressure (local), and osteonecrosis and adrenal insufficiency (systemic).
  • Corticosteroids are generally not suitable for long-term uveitis management.

Conclusions:

  • Corticosteroids are vital for acute uveitis management.
  • Careful consideration of side effect profiles is necessary.
  • Alternative long-term strategies are required for most uveitis cases.